Trials / Completed
CompletedNCT05020249
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bimekizumab | Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period. |
| OTHER | Placebo | Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period. |
Timeline
- Start date
- 2021-09-27
- Primary completion
- 2022-09-05
- Completion
- 2022-09-06
- First posted
- 2021-08-25
- Last updated
- 2025-03-18
- Results posted
- 2024-03-22
Locations
9 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05020249. Inclusion in this directory is not an endorsement.